Abstract

Deep learning is currently the most successful machine learning technique in a wide range of application areas and has recently been applied successfully in drug discovery research to predict potential drug targets and to screen for active molecules. However, due to (1) the lack of large-scale studies, (2) the compound series bias that is characteristic of drug discovery datasets and (3) the hyperparameter selection bias that comes with the high number of potential deep learning architectures, it remains unclear whether deep learning can indeed outperform existing computational methods in drug discovery tasks. We therefore assessed the performance of several deep learning methods on a large-scale drug discovery dataset and compared the results with those of other machine learning and target prediction methods. To avoid potential biases from hyperparameter selection or compound series, we used a nested cluster-cross-validation strategy. We found (1) that deep learning methods significantly outperform all competing methods and (2) that the predictive performance of deep learning is in many cases comparable to that of tests performed in wet labs (i.e., in vitro assays).

For reproduction of material from NJC:
[Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the
Centre National de la Recherche Scientifique (CNRS) and the RSC.

For reproduction of material from PCCP:
[Original citation] - Published by the PCCP Owner Societies.

For reproduction of material from PPS:
[Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the
European Society for Photobiology, the European Photochemistry Association, and
RSC.

For reproduction of material from all other RSC journals:
[Original citation] - Published by The Royal Society of Chemistry.

Information about reproducing material from RSC articles with different licences
is available on our Permission Requests page.